{"id":"sofosbubir-velpatasvir","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3545062","moleculeType":"Small molecule","molecularWeight":"883.02"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir is a nucleotide analog that acts as a chain terminator of the HCV NS5B RNA-dependent RNA polymerase, preventing viral RNA synthesis. Velpatasvir is a non-structural protein 5A (NS5A) inhibitor that disrupts viral replication and assembly. Together, this fixed-dose combination provides direct-acting antiviral activity against multiple HCV genotypes.","oneSentence":"Sofosbuvir inhibits hepatitis C virus NS5B polymerase while velpatasvir inhibits NS5A protein, together blocking viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:38.146Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, all genotypes, with or without cirrhosis"}]},"trialDetails":[{"nctId":"NCT03888729","phase":"PHASE4","title":"Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)","status":"UNKNOWN","sponsor":"Partners in Health","startDate":"2019-08-26","conditions":"Hepatitis C, Chronic","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epclusa"],"phase":"marketed","status":"active","brandName":"sofosbubir/velpatasvir","genericName":"sofosbubir/velpatasvir","companyName":"Partners in Health","companyId":"partners-in-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sofosbuvir inhibits hepatitis C virus NS5B polymerase while velpatasvir inhibits NS5A protein, together blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, all genotypes, with or without cirrhosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}